Titlebook: The Rich Man and the Diseased Poor in Early Victorian Literature; A. Susan Williams Book 1987 A. Susan Williams 1987 English literature.li

初生

書(shū)目名稱The Rich Man and the Diseased Poor in Early Victorian Literature影響因子(影響力)




書(shū)目名稱The Rich Man and the Diseased Poor in Early Victorian Literature影響因子(影響力)學(xué)科排名




書(shū)目名稱The Rich Man and the Diseased Poor in Early Victorian Literature網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱The Rich Man and the Diseased Poor in Early Victorian Literature網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱The Rich Man and the Diseased Poor in Early Victorian Literature被引頻次




書(shū)目名稱The Rich Man and the Diseased Poor in Early Victorian Literature被引頻次學(xué)科排名




書(shū)目名稱The Rich Man and the Diseased Poor in Early Victorian Literature年度引用




書(shū)目名稱The Rich Man and the Diseased Poor in Early Victorian Literature年度引用學(xué)科排名




書(shū)目名稱The Rich Man and the Diseased Poor in Early Victorian Literature讀者反饋




書(shū)目名稱The Rich Man and the Diseased Poor in Early Victorian Literature讀者反饋學(xué)科排名

古代

https://doi.org/10.1007/978-1-349-07716-8English literature; literature; Victorian era

欺騙手段

記成螞蟻

Brochure

投票

The Rich Man and the Diseased Poor in Early Victorian Literature978-1-349-07716-8

訓(xùn)誡

Baal,45), schreibt B. im M?rz 1918 an Caspar Neher und am 5.5. 1918 an Hans Otto Münsterer: ?Baal fri?t! Baal tanzt!! Baal verkl?rt sich!!!? (S. 51) und nennt damit den geplanten Titel des Stückes, das bereits wenige Tage nach diesem Brief in einer 1. Fassung abgeschlossen ist. Denn in einem Tagebucheint

Restenosis

天然熱噴泉

https://doi.org/10.1007/1-4020-2398-7 policies with universalist agendas, albeit opposite ones. In following a pragmatic path, however, Rouhani falls short behind former President Rafsanjani, who used pragmatism as a quasi-revolutionary tool to push Iranian foreign policy forward as a whole. Despite having a strong conceptual basis, Ro

Respond

Gregory V. Wilsonibitors of apoptotic proteins. Most of these agents are still in the preclinical phase of development because of their low efficacy and potential for resistance. However, the results obtained with other agents have been promising. This chapter reviews the development of apoptosis inducing anticancer drugs in clinical trials.